论文部分内容阅读
目的分析以克力芝(LPV/r)为基础的联合方案治疗HIV感染者/艾滋病患者(HIV/AIDS)的临床疗效。方法选取19例因不同原因而改为克力芝为基础,联合替诺福韦、拉米夫定的高效抗反转录病毒治疗方案(HAART)的成人HIV/AIDS患者为研究对象,随访12个月,记录基线、3月、6月、12月时血脂、血糖、体重变化,观察基线、用药后6月、12月时CD4~+T淋巴细胞计数、病毒载量变化。结果基线病毒载量低于检测下限的患者占21.05%(4/19),用药后6月、12月病毒载量低于检测下限的患者分别占73.68%(14/19)和84.21%(16/19),显著高于用药前,差异有统计学意义(P<0.05);基线中位CD4+T细胞计数为185个/mm~3,而用药后6月、12月后中位CD4~+T细胞计数依次为328个/mm~3和396个/mm~3,明显高于用药前(P<0.05);3月、6月、12月后血清三酰甘油水平有不同程度升高(P<0.05),而血糖和体重无明显变化(P>0.05);除此之外,3例患者报告了4项不良反应,予对症处理后仍坚持服药,无严重并发症出现。结论以克力芝(LPV/r)为基础的联合方案治疗对HIV/AIDS患者有效果,可为HIV/AIDS患者提供帮助。
Objective To analyze the clinical efficacy of a combination regimen based on Creutzfeldt-Jakob (LPV / r) in the treatment of HIV / AIDS patients. Methods A total of 19 adult HIV / AIDS patients who were converted to Cremophor and were treated with tenofovir and lamivudine HAART for different reasons were enrolled in this study. Month, recording baseline, blood lipid, blood glucose and body weight in March, June and December. The baseline and the CD4 ~ + T lymphocyte counts and the viral load were observed at 6 and 12 months after treatment. Results The baseline viral load was 21.05% (4/19) when the viral load was lower than the lower limit of detection, and 73.68% (14/19) and 84.21% (16/19% / 19), which was significantly higher than that before treatment (P <0.05). The median CD4 + T cell count was 185 / mm ~ 3 at baseline, and the median CD4 ~ + T cell counts were 328 / mm ~ 3 and 396 / mm ~ 3, respectively, which were significantly higher than those before treatment (P <0.05). Serum triglyceride levels were increased to some extent after March, June and December (P <0.05), but there was no significant change in blood glucose and body weight (P> 0.05). In addition, three patients reported four adverse reactions, and they continued to take the medicine after symptomatic treatment without serious complications. CONCLUSIONS: Combination regimen based on Creutzfeldt-Jakob (LPV / r) is effective in HIV / AIDS patients and may help HIV / AIDS patients.